Marina Alberto
Marina Alberto, PhD, holds a robust academic background in Biotechnology, earning her Bachelor’s Degree and PhD in Science and Technology from Quilmes National University in Argentina. Her research spans cancer immunotherapy, glycan profiling, and vaccine development, including innovative projects on pediatric leukemia diagnosis and cancer-associated carbohydrate-mimetic vaccines. Marina has also contributed extensively to publications in oncology, immunology, and biosimilar development.
She currently serves as a Technical Support and Sales Specialist at Assay Genie.
Connect with Marina or explore her work:
Recent Blogs by Marina:
Indatuximab ravtansine is a CD138-targeting antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other CD138-expressing cancers. By delivering a cytotoxic payload directly to tumor cells, Indatuximab selectively kills cancer cells while sparing healthy tissue. The biosimilar HDBS0014 replicates the efficacy [...]
Gemtuzumab ozogamicin is a CD33-targeting antibody-drug conjugate (ADC) approved for the treatment of acute myeloid leukemia (AML). By selectively delivering a cytotoxic payload to CD33-positive leukemia cells, Gemtuzumab has revolutionized AML therapy. The biosimilar HDBS0015 offers equivalent efficacy and safety as the original [...]
Brentuximab vedotin is a CD30-targeting antibody-drug conjugate (ADC) approved for treating CD30-positive malignancies, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). This ADC combines a monoclonal antibody targeting CD30 with a cytotoxic payload, monomethyl auristatin E (MMAE), to selectively kill [...]
Publications by Marina:
